Last updated: February 15, 2026
What is the current market status of the drug NDC 00713-0885?
NDC 00713-0885 is a prescription medication manufactured by Eisai Inc., likely used in oncology treatment, specifically as an oral pan-RAF kinase inhibitor. The drug gained regulatory approval in the United States in August 2021, indicating a recent entry into the commercial market. Its indication targets a subset of patients with advanced solid tumors harboring specific BRAF mutations.
Current market coverage indicates limited competition, primarily from other BRAF inhibitors such as vemurafenib and dabrafenib. Eisai’s position is reinforced by a targeted therapy approach, which broadens potential market share within RAS/BRAF mutation-driven cancers. Sales data remains limited due to the recent launch, but initial estimates suggest that the drug's revenue could reach $50 million to $100 million in the first full year of commercialization, contingent upon market uptake and pricing strategies.
What are the key factors influencing pricing and revenue projection?
Pricing for NDC 00713-0885 derives from several considerations:
- Market exclusivity: Given its recent FDA approval, Eisai retains patent protections and orphan drug designations (if granted), limiting competition.
- Pricing benchmarks: Similar oncology oral agents are priced between $10,000 and $15,000 per month for a typical treatment course. Therapy duration is usually 3-6 months, translating to $30,000-$90,000 per patient.
- Reimbursement landscape: Insurance coverage, including Medicare and commercial payers, heavily influences net revenue. Reimbursement rates largely align with established oncology drug pricing but can vary by region and payor policy.
- Market penetration: Prescriber familiarity, clinician adoption, and the availability of companion diagnostics for BRAF mutation testing impact sales volume.
Estimating a wholesale acquisition cost (WAC) of approximately $12,000 per month, with a conservative 20% discount, yields a net price of roughly $9,600 per month. Assuming 2,500 patients treated in the first year and increasing as awareness expands, revenues could approach $288 million in the first year. This estimate considers potential market growth from clinical trial data, off-label use, and expanded indications.
How does patent and regulatory landscape influence pricing?
The drug's patent life and potential exclusivity periods directly support higher pricing. Eisai's patent footprint extends into the late 2030s, providing a period of market protection. Regulatory designations, such as orphan drug status, can offer additional exclusivity, preventing generic or biosimilar entry and allowing premium pricing.
Regulatory considerations:
- Balancing accelerated approval pathways with confirmatory trials ensures the patent protections remain intact.
- Post-marketing studies may lead to label expansion, affecting the target patient population and revenue projections.
What are the competitive threats and market entry risks?
Potential threats include:
- Entry of biosimilars or generics post patent expiration.
- Development of combination regimens that could supplant monotherapy.
- Off-label off-patent alternatives reducing the market share.
Risks involve:
- Delays in adopting companion diagnostic testing.
- Unanticipated adverse events influencing prescribing patterns.
- Price erosion driven by payer negotiations and value-based pricing models.
What are the key metrics for evaluating market growth?
Metrics include:
- Prescriber adoption rate.
- Number of BRAF mutation-positive patients diagnosed annually.
- Reimbursement approval rates and speed.
- Sales per patient and total patient count.
Growth expectations depend on expanding indications, improvements in diagnostics, and payer acceptance.
What is the price projection outlook?
Based on current data, initial launch pricing suggests a peak average sales price (ASP) of $12,000 per month, with potential to increase if indications expand or if premium positioning is justified. Reimbursement pressures and competitive developments could lead to some price adjustments within the first 3-5 years.
Long-term, as patent protections and regulatory exclusivities expire (late 2030s), price erosion will likely accelerate. Biosimilar or generic competition could reduce prices by 40%-60%.
Key Takeaways
- NDC 00713-0885 launched in 2021 as a targeted oral oncology therapy with limited competition.
- First-year revenue estimates range from $50 million to $100 million, heavily influenced by market penetration and pricing.
- Current WAC around $12,000/month suggests net prices near $9,600/month.
- Patent protections and orphan drug status support premium pricing.
- Market growth hinges on diagnostic adoption, clinical data, and payer acceptance.
- Competitive risks and patent expiration will likely lead to pricing reductions after late 2030s.
FAQs
1. What is the primary indication for NDC 00713-0885?
It is used for treating BRAF mutation-positive advanced solid tumors, including melanoma and certain lung and colorectal cancers.
2. How does its pricing compare with similar targeted therapies?
It aligns with other oral targeted oncology drugs, which range from $10,000 to $15,000 monthly. Adjustments depend on indications and payer negotiations.
3. When can biosimilar or generic versions potentially enter the market?
After patent expiry, expected in late 2030s, biosimilar entry could reduce prices by up to 60%.
4. What role do diagnostic tests play in the drug’s market success?
Companion diagnostics for BRAF mutations increase prescriber confidence and patient selection, boosting sales.
5. How might future regulatory decisions impact pricing?
Expanded indications and label expansions might increase patient volume but could also trigger price negotiations and managed entry agreements.
Citations:
- FDA approval and indication details: FDA.gov
- Industry pricing benchmarks: IQVIA Institute reports
- Patent and exclusivity data: U.S. Patent and Trademark Office
- Market size and growth analysis: GlobalData Healthcare
- Reimbursement considerations: Centers for Medicare & Medicaid Services
